Clinical Trials Logo
  1. Home
  2. Postmenopausal Osteoporosis
  3. NCT05630768
  4. Details
NCT05630768 Clinical Trial

Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Postmenopausal Osteoporosis Clinical Trial

Official title:
A Multicenter, Open-label, Single-arm Clinical Trial to Evaluate the Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05630768
Other study ID # ATN_PMO_IV
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 3, 2023
Est. completion date February 2025

Study information
Verified date December 2023
Source Dong-A ST Co., Ltd.
Contact Yumie Rhee
Phone +82-2-2228-1973
Email yumie@yuhs.ac
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year

Recruitment information / eligibility
Status Recruiting
Enrollment 155
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender Female
Age group 50 Years to 80 Years
Eligibility Main Inclusion Criteria: 1. Postmenopausal women 2. Patients diagnosed with postmenopausal osteoporosis and administered denosumab for 1 year Main Exclusion Criteria: 1. Any contraindication to risedronate 2. Those evaluated as inappropriate at the discretion of the investigator

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Risedronate Sodium 35 MG [Actonel]
Risendronate Sodium Tab. 35mg, orally, once weekly
• Calcium Vitamin D combination
orally, once daily for concomitant drug

Locations
Country Name City State
Korea, Republic of Severance Hospital Seoul Seodaemun-gu

Sponsors (1)
Lead Sponsor Collaborator
Dong-A ST Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Percent change from baseline in lumbar spine bone mineral density (LS BMD) at 1 year (%) Percent change from baseline in lumbar spine bone mineral density (LS BMD) at 1 year (%) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05902078 - Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis Phase 4
Completed NCT05087030 - Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis Phase 3
Completed NCT01544894 - Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis Phase 4
Completed NCT00377819 - Study of Transitioning From Alendronate to Denosumab Phase 3
Completed NCT00381251 - Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation. Phase 1
Completed NCT00239629 - Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial Phase 4
Completed NCT04026256 - Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration Phase 4
Terminated NCT00529373 - A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) Phase 3
Completed NCT00092014 - A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) Phase 3
Recruiting NCT06079476 - A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. Phase 4
Not yet recruiting NCT04719650 - Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid Phase 4
Recruiting NCT02981732 - CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome N/A
Completed NCT01709110 - VERtebral Fracture Treatment Comparisons in Osteoporotic Women Phase 4
Completed NCT01348243 - Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis Phase 3
Completed NCT00541658 - A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis Phase 3
Completed NCT00395395 - Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women Phase 1
Completed NCT00247273 - A Study of Monthly Risedronate for Osteoporosis Phase 3
Active, not recruiting NCT03720886 - G56W1 in Women With Postmenopausal Osteoporosis Phase 1/Phase 2
Completed NCT01668589 - Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis N/A
Completed NCT04664959 - A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis Phase 3